July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Evaluation of the Trans-Scleral Intravitreous Administration Procedure in Mice and Rats via 3H-Dexran Recovery
Author Affiliations & Notes
  • Craig B Struble
    Covance Laboratories, Madison, Wisconsin, United States
  • Justine Oswald
    Covance Laboratories, Madison, Wisconsin, United States
  • Matt Jensson
    Covance Laboratories, Madison, Wisconsin, United States
  • T Michael Nork
    University of Wisconsin, Madison, Wisconsin, United States
  • Footnotes
    Commercial Relationships   Craig Struble, None; Justine Oswald, None; Matt Jensson, None; T Nork, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 5283. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Craig B Struble, Justine Oswald, Matt Jensson, T Michael Nork; Evaluation of the Trans-Scleral Intravitreous Administration Procedure in Mice and Rats via 3H-Dexran Recovery. Invest. Ophthalmol. Vis. Sci. 2018;59(9):5283.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : This study quantitatively assessed the recovery of radioactivity after intravitreous administration of 3H-Dextran (5000kD) to mice and rats

Methods : Mice and rats (n=4/group) were anesthetized and a bilateral bolus intravitreous injection of 3H-Dextran (approximately 1 uCi/mL) of 0.5 or 1 µL/eye to mice (Groups 1 and 2, respectively) and 1 or 2 µL/eye to rats (Groups 3 and 4, respectively) was administered to each eye using a trans-scleral procedure. A 30-gauge ½” hypodermic needle made the initial opening into the eye (~ 0.5 to 1 mm from the limbus). The intravitreous dose was administered with a blunt 33-gauge needle attached to a 5-µL Hamilton syringe. The needle was visualized in the vitreous humor prior to injection. A cotton tipped applicator (dose wipe) was gently placed on the eye to recover any of the formulation that leaked from the injection site. At ~10 minutes postdose, the animals were euthanized and whole eyes were collected, rinsed with saline, and gently blotted dry. Dose wipes and eyes were analyzed for radioactivity by liquid scintillation counting.

Results : Mean recovery for a 0.5 µL dose in mouse eyes was 31.9%; ranging from 15.3 to 71.3%. The mean dose wipe was 33.4%. Total recoveries ranged from 25.8% to 81.2%, with a mean of 65.3%. Mean recovery for a 1 µL dose in mouse eyes was 36.0%; ranging from 2.24 to 76.7%. The mean dose wipe was 34.7%. Total recoveries ranged from 26.3% to 88.3%, with a mean of 70.8%. Mean recovery for 1 µL in rat eyes was 49.6%; ranging from 13.7 to 89.1%. The mean dose wipe was 11.4%. Total recoveries ranged from 17.7% to 90.1%, with a mean of 61.0%. Mean recovery for 2 µL in rat eyes was 39.5%; ranging from 13.7 to 66.7%. The mean dose wipe was 26.9%. Total recoveries ranged from 46.6% to 83.5%, with a mean of 66.3%.

Conclusions : Retention of a 3H-Dextran (5000 kD) formulation via trans-scleral intravitreous injection in mouse and rat eyes is highly variable. The data suggests that lower volume doses, 0.5 µL dose in mice and the 1 µL dose in rats, provide a slightly higher retention in the eye. However, in each species, at each dose level, the variability of each dose was high such that determining pharmacokinetic parameters, such as Cmax, would be difficult. Results demonstrate that pharmacokinetic and biodistribution data in rats and mice following an intravitreous dose should be interpreted with caution.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.